What happened?
The ACCESS phase 2b trial randomized 230 adults with overweight or obesity to once-daily aleniglipron or placebo. At week 36, placebo-adjusted mean weight change ranged from −8.2% to −11.3% across active-dose groups, without an apparent weight-loss plateau at the end of the double-blind period.
Why does it matter?
Aleniglipron is another example of the shift toward oral small-molecule incretin drugs, which could change cost, supply and patient preference if later trials confirm benefit.
Healthway perspective
Treatment-related discontinuation occurred and gastrointestinal effects remained important. Larger and longer phase III trials are still required.
What this does not mean
It is not yet an approved alternative to semaglutide, tirzepatide or orforglipron.
Medical News is patient education. Research summaries are independently rewritten by Healthway and do not replace individual diagnosis, treatment decisions or specialist advice.